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Abstract
Background: Blood platelet numbers are correlated with growth and aggressiveness of several tumor types,
including hepatocellular carcinoma (HCC). We previously found that platelet lysates (hPLs) both stimulated HCC cell
growth and migration, and antagonized the growth-inhibitory and apoptotic effects of Regorafenib, multikinase
growth inhibitor, on HCC cell lines. We evaluated the effects of human insulin-like growth factor-1 (IGF1), a mitogen
contained in platelets, on the Regorafenib-mediated growth inhibition.
Methods: An Elisa kit was used to evaluate hPL IGF1 concentrations. The effects of IGF1 on cell proliferation were
assessed with MTT assay and analysis of cell cycle progression. Apoptosis assays, scratch assay and Transwell assay
were performed to measure apoptosis, cell migration and invasion respectively. Western blots were performed by
standard protocols.
Results: IGF1 antagonized growth inhibition exerted by Regorafenib on HCC cell lines. Moreover the mitogen
blocked Regorafenib-induced apoptosis and decreased the rate of cell migration and invasion. The IGF1 effects
were in turn antagonized by actions of a potent IGF1 receptor inhibitor, GSK1838705A, showing that the IGF1
receptor was involved in the mechanisms of IGF1-mediated blocking of Regorafenib action. GSK1838705A also
partially blocked the effects of hPLs in antagonizing Regorafenib-mediated growth inhibition, showing that IGF1
was an important component of hPL actions.
Conclusions: These results show that IGF1 antagonized Regorafenib-mediated growth, migration and invasion
inhibition, as well as the drug-mediated induction of apoptosis in HCC cells and reinforce the idea that
microenvironmental factors can influence cancer drug actions.
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Introduction
Hepatocellular carcinoma (HCC) occurs most frequently
in livers that have been chronically damaged by hepatitis
B or C, chronic alcohol ingestion, or a wide range of
chronic metabolic disturbances. Most cases develop in
association with liver fibrosis or cirrhosis, especially in
the presence of hepatitis C, although chronic infection
with hepatitis B can lead to HCC without cirrhosis and
HCC [1, 2]. A consequence of the liver fibrosis is portal
hypertension, with associated splenomegaly, that can
cause thrombocytopenia. The latter has been considered
to be a warning sign of impending HCC development in
patients with chronic virus hepatitis or cirrhosis [3–5].
Thrombocytopenia-associated HCC has recently been
shown to be associated with smaller-size tumors [6, 7].
In contrast, several reports have shown that large size
HCCs often have normal or elevated (thrombocytosis)
platelet counts [8–13], likely due to less portal hyperten-
sion. There are multiple reports of thrombosis and
thrombocytosis in various cancer types [14–20].
Platelets have been shown to be involved in tumor me-
tastasis, as well as in HCC growth, in addition to their
well-recognized role in blood coagulation [21, 22]. Hu-
man platelet lysates (hPL) are a source of many growth
factors and have been recently introduced into clinical
practice as an adjunct to wound healing [23–27]. We
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previously found that hPL have anti-apoptotic effects in
HCC cells and can antagonize the apoptotic and cell
growth inhibitory actions of the multikinase inhibitors,
Sorafenib and Regorafenib [28, 29]. The current work
extends previous findings, by showing that growth in-
hibitory actions mediated by Regorafenib [30] in HCC
cells in vitro can be antagonized by insulin like growth
factor 1 (IGF1), one of the well-described mitogens con-
tained in platelets [25–27]. Furthermore, an IGF1 recep-
tor inhibitor can partially block the drug resistance
actions of hPL, supporting the idea that platelet-




Regorafenib was gifts from the Bayer Corp (West Haven,
CT, USA), recombinant human IGF1 was purchased
from Pepro-Tech (Rocky Hill, NJ, USA), GSK1838705A
was purchased from Selleckchem (Houston, TX, USA).
Hep3B, HepG2 and PLC/PRF/5 human HCC cells were
purchased from the American Type Culture Collection
(ATCC, Rockville, MD, USA). The culture medium was
Dulbecco’s Modified Eagle’s Medium (DMEM). All cell
culture components were purchased from Sigma- Aldrich
(Milan, Italy).
Cell culture
Cells were cultured in DMEM in monolayer culture, and
supplemented with 10 % fetal bovine serum (FBS), 100
U/ml penicillin, 100 μg/ml streptomycin, and incubated
at 37 °C in a humidified atmosphere containing 5 % CO2
in air.
Platelet lysates
The hPL were blood bank time-expired bags, from
healthy volunteers. The study protocol was approved by
the institutional review boards of the University of Bari
and “Saverio de Bellis” Institute of Castellana G. (BA),
Italy. Additionally, written informed consent was ob-
tained from participants for the use of their blood in this
study. The platelet-rich plasma was obtained using an
automated hemapheresis procedure in a local blood
transfusion centre. The platelets obtained from different
volunteers were pooled and then divided into aliquots.
Each aliquot was subjected to three freeze-thaw cycles
to disrupt their membranes and release the growth fac-
tors stored in the granules, producing hPLs.
IGF1 concentrations in platelet lysates
The Human IGF1 ELISA kit (Wuhan Boster Biological
Technology LTD, Wuhan, China) was used for the in
vitro quantitative determination of human IGF1 in FBS
(control) and serial dilution of hPL, according to the
user’s guide.
Growth assay
The cells were cultured in 1 % FBS medium containing
IGF1 40 ng/ml, the concentration was derived from the
IGF1 ELISA dosage in hPL, or hPL corresponding to
3.75 × 107 platelets/ml or equivalent percentage of FBS in
presence of 1 μM (HepG2 cells) or 5 μM (Hep3B and
PLC/RFP/5) of Regorafenib. In the same growth condi-
tion, HCC cells were cultured in absence or presence of
IGFR inhibitor, GSK1838705A 1 μM. After defined incu-
bation times, the proliferative response was estimated by
colorimetric 3-(4,5 di-methylthiazol-2-yl)-2,5-diphenyltet-
razolium bromide (MTT) test. The trypan blue exclusion
assay was used to evaluate cell viability. Each experiment
was performed in triplicate and repeated three times.
Cell cycle analysis
PLC/PRF/5 were synchronized by using thymidine
0.2 M added to the medium. After 18 h of incubation,
the medium containing thymidine was replaced with
fresh medium for 9 h, and then cells were treated with
thymidine for an additional 17 h. Cells were separated
into two groups: one group was collected for cell cycle
analysis and the other one continued culturing; Regoraf-
enib 5 μM, IGF1 40 ng/ml and GSK1838705A 1 μM
were added, and after 6 h of treatment cells were col-
lected to be processed, according to the user’s guide,
with the Muse Cell Cycle Kit (Millipore, Darmstadt,
Germany) which determines the percentage of cells in
the G0/G1, S and G2/M phases of cell cycle with the
Muse Cell Analyzer.
Migration assay
A scratch assay was performed as previously described
[31, 32]. Briefly, a wound was generated with a pipette
tip, after rinsing, medium containing IGF1 40 ng/ml or
1 % FBS (control) alone or in combination with Regoraf-
enib 1 μM and/or GSK1838705A 1 μM. Photographs
were taken of each well immediately (T0) and after 24 h
(T1), 48 h (T2) and 72 h (T3). The values were ex-
pressed as percentage of migration, with 100 % being
when the wound was completely closed. The results
were representative of three independent experiments.
Invasion assay
Cell invasion assays were performed using Matrigel (BD
Transduction, San Jose, CA, USA)-coated Transwells
(8 μm pore PET membrane, Millipore, Billerica, MA,
USA) as previously described [31]. Briefly, Regorafenib
5 μM and/or GSK1838705A 1 μM treated cells were sus-
pended in low serum medium. Medium containing IGF
40 ng/ml or FBS was added to the bottom wells. After
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incubation of 24 h, the invading cells were fixed and
stained. The images were acquired and analyzed count-
ing the cells with Image J Software (National Institute of
Health, USA). Values obtained were expressed as per-
centage of invading cells, setting the cell counts of con-
trol cells as 100 %. Results were representative of three
independent experiments.
Apoptosis assays - Annexin V
The Muse Annexin V/Dead Cell Assay Kit (Millipore,
Darmstadt, Germany) for quantitative analysis of live,
early/ late apoptotic and dead cells was used with a
Muse Cell Analyzer (Millipore). Briefly, the assay utilizes
Annexin V to detect PS on the external membrane of
apoptotic cells. A dead cell marker (7-AAD) is also used.
PLC/PRF/5 cell line, including positive and negative
controls, were cultured in 1 % FBS medium in presence
of Regorafenib 5 μM alone (control cells) or in combin-
ation with IGF1 40 ng/ml or IGF1 40 ng/ml and
GSK1838705A 1 μM for 48 h. The cells were then proc-
essed as described in the user’s guide.
Western blots
MAPK signaling and anti-apoptosis markers in cells
treated with Regorafenib 5 μM and IGF1 40 ng/mL were
analyzed by Western blot, as previously described [31].
Briefly, cells were washed twice with cold PBS and then
lysed in RIPA buffer (Sigma-Aldrich, Milan; Italy). After
quantization of protein concentration, equal amount of
protein (50 μg) were resolved on SDS–PAGE and trans-
ferred to polyvinyldifluoride (PVDF) filters. The blots
were blocked with 5 % (w/v) nonfat dry milk for 2 h at
room temperature and then probed with primary anti-
body overnight at 4 °C.
The primary antibodies were directed against the follow-
ing proteins: IGFR-1 and phospho-IGFR-1 (p-IGFR-1),
ERK and phospho-ERK (p-ERK), BRAF and phospho-
BRAF (p-BRAF), c-Myc and phospho-c-Myc (p-c-Myc),
JNK and phospho-JNK (p-JNK), STAT3 and phospho-
STAT3 (Tyr705, Ser727) (p-STAT3), p38 and phospho-
p38 (p-p38), Bim, Bid, Bad, phospho-survivin (p-survivin),
survivin, Bcl-xL, Bcl-2 and β-actin (Cell Signaling, Beverly,
MA, USA). After three washes, incubation was followed
by the reaction with horseradish peroxidase-conjugated
secondary antibody for 1 h at room temperature. The im-
munoreactive bands were visualized and analyzed using
enhanced chemiluminescence detection reagents, accord-
ing to the manufacturer’s instructions, and chemilumines-
cence detection system (ChemiDoc XRS apparatus and
software, Bio-Rad, Milan, Italy).
Statistical analysis
GraphPad Prism 5.0 software (La Jolla, CA, USA) was used
for all statistical analysis. Mann–Whitney nonparametric
test was employed to assess the statistical significance of
differences between two groups. For multiple comparisons
was used one-way Anova test followed by appropriate
post-test. p < 0.05 was considered statistically significant.
All experiments were done in triplicate and data are pre-
sented as mean ± standard deviation (SD).
Results
Antagonism by IGF1 of Regorafenib-mediated inhibition
of HCC cell growth
hPL were previously examined for the ability to antago-
nize Regorafenib-mediated inhibition of human HCC cell
line growth [29]. To further investigate the role of IGF1,
one of the known platelet growth factors, in antagonizing
Regorafenib actions on HCC cells, we initially measured
IGF1 levels in hPL as described in Materials and Methods.
The results showed concentrations of 40 ng/ml of IGF1
were present in hPL, corresponding to 3.75 × 107 plate-
lets/ml. This IGF1 concentration range was used in the
subsequent experiments.
Hep3B, PLC/PRF/5 and HepG2 human HCC cell lines
were treated in log phase growth in culture dishes with
Regorafenib 1–5 μM or IGF1 40 ng/ml alone or in com-
bination with appropriate controls and proliferation was
evaluated by MTT assay.
We found that IGF1 significantly antagonized the
growth inhibitory actions of Regorafenib. We found that
in all HCC cell lines that were examined, IGF1, added in
combination with Regorafenib, significantly increased
the proliferation rate of about 60 %, compared to the
same cells treated only with Regorafenib. This effect was
only partial because the proliferation rate of IGF1/R
treated cells was still lower than both IGF1 (42 %) and
control (15 %) cells and was blocked by GSK1838705A,
a potent inhibitor of IGF1 receptor, used at a non- toxic
concentration (1 μM) that did not by itself affect prolif-
eration (Fig. 1a).
We next investigated if the timing of the IGF1 addition
might affect Regorafenib-mediated growth inhibition. For
this purpose, two different culture conditions were used.
In the first condition, cells that had been previously cul-
tured for 48 h with IGF1 40 ng/ml or equivalent percent-
age of FBS (control) were then treated with Regorafenib
5 μM for the next 24 h. In the second condition, cells that
had been pre-treated for 24 h with Regorafenib were sub-
sequently cultured for the next 48 h in the presence of
IGF1 or FBS. In Regorafenib-treated cells, IGF1 pre-
treatment led to an increase in the proliferation rate
(40 %) compared to the proliferation rate observed in
cells treated only with drug (Fig. 1b). Moreover, IGF1
partially reversed (28 %) the Regorafenib-mediated
growth inhibition if added after drug administration.
These results confirmed our previous findings in which
the reversible effect of Regorafenib was shown [33].
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Fig. 1 (See legend on next page.)
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The antagonism exerted by IGF1 on Regorafenib-
mediated growth inhibitory actions was also observed
on cell cycle progression. Regorafenib caused an inhibi-
tion in the progression from S phase of the cell cycle to
G2/M phase. After 6 h (T1) from block release (T0),
Regorafenib treated cells in G2/M phase were only 0.2
times more than the control cells at T0, while the
number of control cells in G2/M phase at T1 were 1.5
times more with respect the number of control cells at
T0 (Fig. 1c). IGF1 counteracted the Regorafenib-
mediated block in cell cycle progression (0.85 times
more than the control cells at T0), and the IGFR
antagonist, GSK1838705A, abrogated this effect.
Antagonism by IGF1 of Regorafenib-mediated induction
of apoptosis
The effects of IGF1 on Regorafenib–mediated apoptosis, a
major aspect of its growth-inhibitory effects, were then
examined. Regorafenib induced an increase in cellular
Annexin V. When IGF1 was also added to the cell
medium together with Regorafenib, a pronounced and sig-
nificant antagonism of apoptosis induction was found and
this antagonism was abrogated by the IGFR inhibitor
GSK1838705A 1 μM (Fig. 2a). Major apoptosis markers in
cells treated with Regorafenib alone or in combination
with IGF1 were then examined. We found that pro-
apoptotic marker (Bim, tBid and Bad) levels increased
in the presence of Regorafenib alone and anti-apoptotic
markers (p-survivin, Bcl-xL and Bcl-2) decreased under
the same conditions. However, in cells treated with
Regorafenib in combination with IGF1 (Fig. 2b), we
found that IGF1 antagonized these Regorafenib effects
on induction of apoptosis.
Antagonism by IGF-1 of Regorafenib-mediated inhibition
of cell migration and invasion
Regorafenib inhibits both HCC cell migration, as well as
cell invasion through Matrigel membranes [31]. IGF1
40 ng/ml was then added to cells in the presence of
Regorafenib 5 μM, a concentration that can inhibit both
migration and invasion in HCC cells. We found that IGF1
antagonized the inhibition by Regorafenib of both migra-
tion and invasion and these effects were also abrogated by
GSK1838705A 1 μM (Fig. 3a/b).
IGF-1 as a major contributor to hPL actions
The above results using GSK1838705A, showed that IGF1
receptors were involved in the mechanisms of IGF1-
mediated antagonism of Regorafenib effects. We then
examined the possibility that the blocking effects of hPL
on Regorafenib that had been previously noted, might be
attributable mostly to IGF1 presence in platelet lysates
[28]. We found that the platelet lysates increased the pro-
liferative rate of Regorafenib-treated cells by 84 %. This
effect was attributed to IGF1 action for 41 %, as demon-
strated adding GSK1838705A 1 μM to the platelet lysates,
and the remaining 43 % was due to the combined effects
exerted by all the other growth factors included in platelets
(Fig.4).
Effects of IGF1 on cell signaling
Regorafenib has previously been shown [28] to cause a de-
crease in p-ERK levels, consequent on Raf inhibition. We
next examined the effects of Regorafenib on cellular
MAPK signaling pathway marker levels in cells that were
treated in the absence or presence of IGF1. We found that
IGF1 antagonized the Regorafenib-mediated decrease in p-
BRAF and p-ERK levels, and also antagonized the de-
creases in the levels of p-c-Myc, p-p38 and p-STAT3
(Tyr705, Ser727). By contrast, the Regorafenib-mediated
increases in p-JNK levels were decreased by the addition of
IGF1 to the cultures (Fig. 5a). These actions of IGF1 were
in turn blocked by the presence in the cultures of
GSK1838705A, indicating the involvement of the IGF1 re-
ceptors. IGF1 thus counteracted Regorafenib actions on
signaling intracellular markers (Fig. 5b/c).
Discussion
Platelets and their contained growth factors have be-
come of great interest in tumor biology, due to their
contribution to the tumor microenvironment, their con-
tent of many growth and inflammatory factors, and to
their identification as important contributors to tumor
growth and metastasis, including HCC, as well as to nor-
mal liver regeneration [21, 22, 34–36]. Amongst the
many factors in platelet granules, IGF1 has received con-
siderable attention, due to its involvement in HCC
growth and prognosis [37–39] and as a possible target of
anti-cancer and anti-HCC therapies.
(See figure on previous page.)
Fig. 1 Antagonism by IGF1 of Regorafenib-mediated growth inhibition of HCC cell Lines. a. Hep3B, PLC/PRF/5 and HepG2 cells were cultured in
presence of Regorafenib 1–5 μM, IGF1 40 ng/ml, GSK1838705A 1 μM. MTT assay was assessed after 48 h (48 h). b. PLC/PRF/5 cells were cultured
in presence of Regorafenib 5 μM and IGF1 40 ng/ml in different time conditions. In the first group (light gray) the cells previously treated with
IGF1 for 48 h received Regorafenib for the following 24 h. In the second group (dark gray) the cells, previously treated with Regorafenib for 24 h,
received IGF for the following 48 h. MTT assay was assessed after 72 h. c. PLC/PRF/5 cells were synchronized in the S phase of the cell cycle using
thymidine 0.2 M (T0), after 6 h from block release (T1), the cells were processed with the Cell Cycle Kit and analyzed with Muse Cell Analyzer to
evaluate the percentage of cells in G0/G1, S and G2/M phases. The panels represent an example of DNA content profile in different treatment
conditions. The mean of three independent experiments was plotted in the relative graph, where the values are calculated as fold increase of the
cells in G2/M at T1 respect to control cells at T0. The results of three independent experiments are expressed as means ± SD. ***p < 0.0001
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Fig. 2 Antagonism by IGF1 of Regorafenib-mediated induction of apoptosis. a. PLC/PRF/5 cell line cultured in 1 % FBS medium was treated with IGF1
40 ng/ml in combination with Regorafenib 5 μM and GSK 1 μM. The Muse Annexin V kit was used to evaluate the percentage of apoptotic cells. The
means ± SD of three independent experiments is plotted in the relative graph. ***p < 0.0001. b. Representative Western blot that shows anti-apoptotic
(phospho-survivin, Bcl-xL and Bcl-2) and pro-apoptotic (Bim, truncated-Bid and Bad) proteins in PLC/PRF/5 cells treated as described above
Fig. 3 Antagonism by IGF1 of regorafenib-mediated inhibition of migration and invasion. PLC/PRF/5 cell line cultured in 1 % FBS medium was
treated with IGF1 40 ng/ml alone or in combination with Regorafenib 5 μM and GSK 1 μM. a. Migration assay was performed as described and
the microscopic analysis was assessed at the time of the scratch (T0) and after 48 h (T2). The values were expressed as percentage of migration,
where 100 % represents the scratch completely closed. b. The percentage of invasion was calculated comparing the invading drug-treated cells
to drug-untreated control cells (100 %). The results of three independent experiments are expressed as means ± SD. ***p < 0.0001
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Regorafenib is a multikinase inhibitor and its action is
similar of Sorafenib [40]. Sorafenib is a small multi-
target inhibitor that has broad-spectrum activity against
several tyrosine kinases. Although initially described as a
b-Raf inhibitor, Sorafenib inhibits the activity of several
cell surface receptor tyrosine kinases [40]. A constitutive
activation of receptor tyrosine kinases is a common fea-
ture of many types of cancers, particularly those of soft
tissue origin where their concerted expression has been
shown to promote tumor growth and survival [41].
Regorafenib blocks ERK action, an intracellular signaling
involved in HCC cell proliferation [32].
Also Regorafenib has an indirect effect of p38 kinase,
JNK and Stat3 involved in tumorigenesis and HCC pro-
liferation. In this study we explored the action of IGF1
in HCC cells in vitro. We found that IGF1 antagonized
the growth inhibitory effects of Regorafenib. The
insulin-like growth factor (IGF) pathway has highly con-
served functions in mammals and plays a critical role in
energy metabolism and cell renewal in response to nu-
trients. IGF pathway is not only involved in cell growth
in tissue culture, but it also promotes cell proliferation,
migration and transformation into malignancy [42]. The
Fig. 4 Effects of IGF1 receptor (IGFR1) inhibitor (GSK1838705A)
on Regorafenib-mediated growth inhibition in PLC/PRF/5 cells.
PLC/PRF/5 cells were cultured in 1 % FBS medium in presence
of IGF1 40 ng/ml or platelet lysate corresponding to 3.75 × 107
platelets/ml, Regorafenib 5 μM and GSK1838705A 1 μM, using the
conditions indicated in the graph. MTT assay was assessed after
48 h. The results of three independent experiments are expressed
as mean ± SD. **p < 0.001; ***p < 0.0001
Fig. 5 MAPK signaling and IGFR1 expression in PLC/PRF/5 cells. a. Western blot of MAPK proteins that shows IGF1 antagonism effect on Regorafenib
action in PLC/PRF/5 cells. b. Activated IGF1 receptor (IGFR1) after treatment with Regorafenib (R), IGF1, IGF1 + R, IGF1 + GSK and IGF1 + R + GSK,
respectively. c. IGF1 effect on the BRAF protein that is direct Regorafenib target
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anti-apoptotic property of IGF-1R was shown in its re-
sponse to p53, the tumor suppressor gene that promotes
apoptosis [42]. Wild type p53 expression inhibited the
gene expression of IGF-1R, while mutant p53 increased
the gene expression of IGF-1R. Oncogenes such as Src
kinase and Akt kinase both stimulated the gene expres-
sion of IGF-1R, providing more evidence that IGF-1R is
vital in carcinogenesis [43]. In addition, IGF-1R also
stimulates cell mobility, as demonstrated by its activity
in melanoma cell lines. Another important role of IGF-
1R in carcinogenesis is its ability to transform and main-
tain the transformed phenotype [42]. IGF1 and its bind-
ing to its receptor induce activations of two major
intracellular cascades, the phosphatidyl inositol 3-kinase
(PI3K) and the mitogen-activated protein kinase (MAPK),
both of which result in cell differentiation, proliferation
and anti-apoptosis [43]. Particularly in HCC, IGF-1R is
overexpressed and can induce carcinogenesis. In a study
where 10 HCC cell lines (including PLC/PRF/5 cell line)
were tested, all of them showed elevated IGF-1R mRNA.
Furthermore, the addition of IGF-1 to the PLC/PRF/5 cell
line induced increased cell proliferation in a dose
dependent manner, showing that the major tumor pro-
moting effects of IGF ligands on HCC are exerted through
IGF-1R [42–44].
The IGF1 signaling pathway provides an important
regulatory mechanism for tumorigenesis and drug resist-
ance in HCC [41].
We found that IGF1, used in the same concentration
as was measured in hPL, significantly antagonized the
growth inhibitory actions of Regorafenib. This effect
was blocked by GSK1838705A, a potent inhibitor of
IGF1 receptors, used at non-toxic concentrations that
do not affect proliferation. We next found that IGF
pre-treatment protected the cells from subsequent
addition of Regorafenib to the cultures and antagonized
Regorafenib-mediated growth inhibition, which was re-
duced by 40 % when the cells were pre-treated with
IGF1. This suggested that IGF1 signalling is implicated
in the observed Regorafenib resistance or that a major
mechanism of Regorafenib-mediated growth control is
exerted through interference in the IGFR pathway,
which is then counteracted by addition of IGF1 [42].
Moreover, the Regorafenib pre-treatment modified the
stimulatory action ensuing to the addition of the IGF1.
Regorafenib-mediated inhibition of cell growth was
only partially rescued by subsequent IGF1 treatment
(28 %), showing that Regorafenib treatment, even if re-
versible, modified the cells [43].
A corollary is that IGFR inhibitors might enhance the
growth inhibitory actions of Regorafenib, since IGF1 can
block the drug effects on cell growth. Our results on cell
cycle progression support the idea of antagonism exerted
by IGF on Regorafenib-mediated growth inhibition.
An important mechanism of resistance to IGFR inhibi-
tors is the compensatory activation of related signalling
pathways [44]. We observed that IGF1 changed intracel-
lular signalling in HCC cells. We found that levels of the
proliferation markers p-BRAF, p-ERK, p-p38 and p-Stat3
(Tyr705, Ser727) were decreased by Regorafenib action.
By contrast, IGF1 addition to the cultures antagonized
Regorafenib action and levels of the proliferation
markers increased. We, also, found that levels of apop-
tosis markers were influenced by IGF1 actions, since
pro-apoptotic markers (p-JNK, p-c-Jun, Bim, Bad and
Bid) decreased with IGF1, while anti-apoptosis markers
(survivin, BCL-xL and Bcl-2) increased. Survivin is an
apoptosis-inhibitory protein that is over-expressed in
multiple cancer types, including HCC, plays critical roles
in regulating apoptosis, cell proliferation and survival
and has been shown to be a direct downstream target of
IGF1 pathway [44].
Regorafenib decreased p-survivin levels and this was
also antagonized by addition of IGF1. GSK1838705A
reversed the IGF1 actions, showing that the antagonist
effects of IGF are exerted through its receptor. The an-
tagonism exerted by IGF on Regorafenib effects was
also shown for drug mediated apoptosis, as a decrease
in Annexin V levels and in the Caspase 3/7 activation.
Pre-clinical studies have shown that the efficacy in anti-
cancer therapy for HCC can be improved by inhibiting
the IGF signalling pathway in HCC cells [45].
Several new inhibitors of IGF1 or its receptor are in cur-
rent clinical trials for HCC, including Octreotide (Novartis),
a Somatostatin analog and MEDI 573 (Astrazeneca), tar-
geting either IGF1 and or IGFII, as well as Linsitinib (OSI
Pharmaceuticals), Cixutumumab (ImClone), AVE1642
(Sanofi-Aventis), which are IGF receptor antagonists.
However, the relationship of IGF1 levels in serum and
tumor tissue and of its receptor levels with HCC growth
and prognosis are very complex [37]. It has recently been
shown that one of the many mechanisms of Sorafenib
(Regorafenib is Fluoro-Sorafenib) action on HCC cell
growth is via an inhibition of IGF1 [39]. Furthermore,
IGF1 has been shown to be involved in resistance to
cytotoxic chemotherapy by several drugs and on a variety
of tumor types, mainly through an anti-apoptotic effect
[33, 46–51], as we have found in the current work.
Conclusion
These experiments highlight the importance of the
microenvironment, including IGF1, in modulating the
growth inhibitory effects of anti-HCC therapeutic drugs.
By contrast, anti-IGF or anti-IGF receptor agents might
be predicted to be therapeutically useful in enhancing
the activity of anti-HCC therapies. Finally, we re-enforce
the concept of drug resistance mediated by factors in the
tumor microenvironment, and also summarize potential
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drug targets based on the current knowledge of the
tumor microenvironment [52].
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